Skip to main content
Contact Us
Subscribe
E-Edition
96°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
113.10
-0.21 (-0.19%)
Streaming Delayed Price
Updated: 2:22 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Merck & Co
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
71
72
Next >
Looking Into Merck & Co's Recent Short Interest
December 25, 2023
Via
Benzinga
January Effect: 3 Under-the-Radar Stocks Poised for a New Year Jump
December 24, 2023
Are you looking to profit from the January effect? Here are three under-the-radar stocks poised for a new year's jump.
Via
InvestorPlace
7 Small-Cap Stocks That Wall Street Loves for Good Reason
December 22, 2023
The market rally is showing signs of broadening to include small-cap stocks, here are seven that analysts are upgrading
Via
InvestorPlace
7 Best Dow Jones Stocks to Buy for Conservative Investors
December 21, 2023
With many vagaries still surrounding the market, the best Dow Jones stocks for conservative investors offers a safer approach.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
Merck's Chronic Cough Treatment Candidate Receives Second Time FDA Rejection
December 21, 2023
The FDA issued a Complete Response Letter (CRL) regarding Merck & Co Inc's (NYSE: MRK) New Drug Application (NDA) for gefapixant under development for the treatment of refractory chronic cough (RCC) or...
Via
Benzinga
Exposures
Product Safety
(MRK) - Analyzing Merck & Co's Short Interest
December 04, 2023
Via
Benzinga
Price Over Earnings Overview: Merck & Co
November 30, 2023
Via
Benzinga
Analyst Ratings for Merck & Co
November 29, 2023
Via
Benzinga
Better Dividend Stock: Bristol Myers Squibb or Merck?
December 19, 2023
These two pharma stocks have sizable dividend yields. Which is the better buy right now?
Via
The Motley Fool
Jim Cramer Slams FTC Chair Lina Khan's Policies For Hampering Investor Returns: 'One-Woman Wrecking Crew For Your Stock Portfolio'
December 18, 2023
He posits that such actions have negatively impacted stock valuations.
Via
Benzinga
3 Stocks Down 30% or More This Year That Wall Street Expects to Skyrocket in 2024
December 18, 2023
Analysts think these beaten-down stocks could rebound strongly in the new year.
Via
The Motley Fool
Moderna Just Took a Step Closer to Its Product Launch Goal. Is the Stock a Buy?
December 18, 2023
Moderna's personalized cancer vaccine candidate just delivered excellent clinical trial results.
Via
The Motley Fool
Contaminated Vaccines: FDA Reportedly Finds Cleaning And Expiry Lapses At Moderna's Massachusetts Facility
December 16, 2023
The U.S. Food and Drug Administration (FDA) identified several quality control issues at the primary manufacturing facility of Moderna Inc. (NASDAQ: MRNA)
Via
Benzinga
Exposures
Product Safety
What's Going On With C4 Therapeutics Stock?
December 15, 2023
C4 Therapeutics, Inc. (NASDAQ: CCCC) shares are trading higher Friday, and the stock has gained more than 350% over the past five days.
Via
Benzinga
FDA Approves Merck's Drug Belzutifan For Type Of Advanced Kidney Cancer In Pretreated Cancer Patients
December 15, 2023
The FDA approved Merck & Co Inc's (NYSE: MRK) Welireg (belzutifan), an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for adult patients with advanced renal cell carcinoma (RCC) following a...
Via
Benzinga
Exposures
Product Safety
MRNA Stock Surges as Moderna Teams Up With Merck to Fight Cancer
December 14, 2023
Moderna is in focus after reporting positive results for its cancer treatment today, with MRNA stock surging more than 9%.
Via
InvestorPlace
Moderna CEO Highlights Promising Cancer Vaccine Data: 'Think About The Number Of Lives That Can Be Impacted'
December 14, 2023
Moderna, Inc. (NASDAQ: MRNA) CEO Stéphane Bancel appeared on CNBC's "Squawk Box" Thursday to discuss the company's promising new cancer vaccine developed in
Via
Benzinga
Why Is Moderna (MRNA) Stock Up 11% Today?
December 14, 2023
Moderna stock is on the rise Thursday as investors in MRNA react to positive results from a skin cancer vaccine in a Phase 2b trial.
Via
InvestorPlace
Moderna Stock Is Soaring Today - Here's Why
December 14, 2023
Moderna Inc (NASDAQ: MRNA) and Merck & Co Inc (NYSE: MRK) announced follow-up data from the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study of mRNA-4157 (V940), an investigational individualized...
Via
Benzinga
Moderna's Cancer Vaccine Cuts Risk Of Relapse, Death By 49%; Will Shares Jump?
December 14, 2023
Moderna and Merck are already working on a Phase 3 study, but these are long-running tests.
Via
Investor's Business Daily
Pfizer's 2024 Outlook Disappointed Wall Street, But Where Will the Stock Be in 5 Years?
December 14, 2023
Pfizer recently outlined expectations for 2024 results in light of an upcoming $43 billion acquisition of Seagen.
Via
The Motley Fool
Dow Jones Skyrockets To Record Heights, Shatters 37,000 Mark, Fueled By Fed's Dovish Stance
December 13, 2023
The 30 largest blue-chip stocks in the Dow Jones Industrial Average surged to unprecedented highs following the Federal Reserve's decision to keep interest rates steady.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
What's Going On With Moderna Stock Today?
December 12, 2023
Moderna Inc (NASDAQ: MRNA) announced changes to its operating model to bring focus to its short- and
Via
Benzinga
Why Is C4 Therapeutics (CCCC) Stock Up 72% Today?
December 12, 2023
C4 Therapeutics stock is rising higher on Tuesday as investors in CCCC shares celebrate a new collaboration agreement with Merck.
Via
InvestorPlace
Why Is Cancer-Focused C4 Therapeutics Stock Soaring Today?
December 12, 2023
C4 Therapeutics Inc (NASDAQ: CCCC) has entered into an exclusive license and collaboration agreement with Merck & Co Inc (NYSE: MRK) to develop degrader-antibody conjugates (DACs), an emerging modality...
Via
Benzinga
Biotech Is Coming Back, Can The Run Last?
December 11, 2023
The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally.
Via
Talk Markets
Merck, Eisai Report Yet Another Failure For Keytruda Plus Lenvima Combo Trial, This Time In Endometrial Cancer
December 08, 2023
Merck & Co Inc (NYSE: MRK) and Eisai Co Ltd (OTC: ESALY) (OTC: ESALF) announced that the Phase 3 LEAP-001 trial of Keytruda (pembrolizu
Via
Benzinga
Double Flops For Merck's Lung Cancer Studies
December 07, 2023
Merck & Co Inc (NYSE: MRK) announced full results from the Phase 2 KeyVibe-002 trial of vibostolimab/pembrolizumab combo, with or without docetaxel for metastatic non-small cell lung cancer (NSCLC)...
Via
Benzinga
5 Dividend Stocks That Recently Increased Their Payouts
December 06, 2023
One stock increased its dividend by 25%.
Via
The Motley Fool
Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments
December 02, 2023
LianBio received a $465 million buyout offer from Tang Capital Management. In addition, Tang also offered shareholders a contingent value right for 80% of net proceeds from any license or divestment of...
Via
Talk Markets
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
71
72
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.